Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689734 | 0.90 | OPRM1 (0.44) | OPRM1OPRD1OPRK1SPHK1 | |
| SCHEMBL5690258 | 0.89 | GRIN2B (0.53) | OPRM1OPRD1OPRK1SPHK1 | |
| SCHEMBL5690254 | 0.89 | GRIN2B (0.53) | OPRM1OPRD1OPRK1SPHK1 | |
| SCHEMBL7072271 | 0.84 | GRIN2B (0.50) | OPRM1OPRD1OPRK1SPHK1 | |
| SCHEMBL7072272 | 0.84 | GRIN2B (0.50) | OPRM1OPRD1OPRK1SPHK1 | |
| SCHEMBL5689666 | 0.83 | KDM4E (0.52) | SPHK1 | |
| SCHEMBL7023319 | 0.83 | KDM4E (0.52) | SPHK1 | |
| SCHEMBL5689661 | 0.83 | KDM4E (0.52) | SPHK1 | |
| SCHEMBL6485638 | 0.81 | SPHK1 (0.43) | OPRM1OPRD1OPRK1SPHK1 | |
| SCHEMBL6486349 | 0.81 | SPHK1 (0.43) | OPRM1OPRD1OPRK1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | claimed |
| CN-1441773-A | Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists | WARNER LAMBERT CO (US) | 2003-09-10 | — | — | CN | claimed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | claimed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-6919377-B2 | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists | WARNER LAMBERT COMPANY LLC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | disclosed |
| CN-1441773-A | Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists | WARNER LAMBERT CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | GRIN1, GRIN2A, GRIN2B | KMT2A 1532/4885OPRM1 18/4885OPRD1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.